Zenith Drugs has announced a board meeting and is rapidly advancing its new Cephalosporin manufacturing facility in Indore, built to European GMP standards.

The plant will produce tablets, capsules, dry powder, and injections, with commercial production slated for September 2025. This expansion enhances Zenith’s manufacturing capabilities and positions it strongly for growth in regulated markets, supporting potential revenue growth.